Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Agregado de agonistas beta‐2 intravenosos a los agonistas beta‐2 inhalados para el asma aguda

Información

DOI:
https://doi.org/10.1002/14651858.CD010179Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 12 diciembre 2012see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Vías respiratorias

Copyright:
  1. Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Andrew H Travers

    Correspondencia a: Department of Emergency Medicine and Community Health and Epidemiology, Emergency Health Services, Nova Scotia, Canada

    [email protected]

  • Stephen J Milan

    Population Health Sciences and Education, St George's, University of London, London, UK

  • Arthur P Jones

    c/o Cochrane Airways Group, London, UK

  • Carlos A Camargo Jr

    Department of Emergency Medicine, Massachusetts General Hospital, Boston, USA

  • Brian H Rowe

    Department of Emergency Medicine, University of Alberta, Edmonton, Canada

    School of Public Heath, University of Alberta, Edmonton, Canada

Contributions of authors

Travers A: Initiated the review, wrote the protocol, performed searches, performed quality assessments, entered data and performed analysis, and primary author of review. Jones AP: study selection, quality assessment, review of protocol; Camargo CA Jr: Protocol development, methodological input, statistical support, manuscript review at an early stage of this review's development; Rowe BH: Co‐authored protocol, performed selection for inclusion and quality assessment, data extraction and data entry, manuscript review, conversion to RevMan at an early stage of this review's development, and as assigned editor for the Cochrane Airways Group. Milan SJ and Welsh E independently selected trials for inclusion from initial searches, and Travers A and Milan SJ independently selected trials for inclusion from full trial reports. Milan SJ and Travers A updated the 'Risk of bias' tables for trials already included in the review and similarly for any new trials identified in the update. Milan SJ entered data and this was verified by Cates C. Milan SJ drafted the review and further development was provided by Travers A and Cates C.

Sources of support

Internal sources

  • University of Alberta, Faculty of Medicine & Dentistry, Canada.

  • Alberta Heritage Foundation for Medical Research (AHFMR), Canada.

  • NHS Research and Development, UK.

  • National Institute for Health Research (SJM), UK.

External sources

  • Canadian Association of Emergency Physicians (CAEP), Canada.

  • National Heart, Lung and Blood Institute (HL‐03533 NIH; CA Camargo, Jr), USA.

  • Canadian Institutes of Health Research (CIHR), Ottawa, ON (BH Rowe), Canada.

Declarations of interest

None. The authors are not involved in the primary research reported in this systematic review and have not represented the producers of these agents in the past.

Acknowledgements

We would particularly like to acknowledge the excellent support and assistance from Emma Welsh, Liz Stovold, and Emma Jackson of the Cochrane Airways Review group, together with the greatly appreciated guidance from Chris Cates (Cochrane Airways Review Group Co‐ordinating Editor). We are most grateful to Karen Kelly and Samantha Barker for their assistance with data extraction, entry and review at an early stage of this review's development, and we are particularly grateful to Toby Lasserson, Luis Nannini and Taixiang Wu for their help with the translation of potentially relevant non‐English trials. The support provided by librarians Judith Scammel, Jane Appleton and Hilary Garrett at St George's University of London is also greatly appreciated.

Version history

Published

Title

Stage

Authors

Version

2012 Dec 12

Addition of intravenous beta<sub>2</sub>‐agonists to inhaled beta<sub>2</sub>‐agonists for acute asthma

Review

Andrew H Travers, Stephen J Milan, Arthur P Jones, Carlos A Camargo Jr, Brian H Rowe

https://doi.org/10.1002/14651858.CD010179

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.